Evidence map›Paper›PMID 38314853›Full record

ArticleJournal of the Pediatric Infectious Diseases Society2024

Clinical Outcomes Associated with Amoxicillin Treatment for Acute Otitis Media in Children.

Holly M Frost, Amy Keith, Dana R Fletcher, Thresia Sebastian, Samuel R Dominguez, Melanie Kurtz, Sarah K Parker, Michael L Wilson, Timothy C Jenkins

Open access · greenAbstract read
In one paragraph

Article in Journal of the Pediatric Infectious Diseases Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Narrow spectrum, broad utility: Reassessing cephalexin and cefazolin beyond cellulitis.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2025
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Holly M FrostDepartment of Pediatrics, Denver Health and Hospital Authority, Denver, CO, USA.ORCID 0000-0002-3016-3287
Amy KeithCenter for Health Systems Research, Denver Health and Hospital Authority, Denver, CO, USA.
Dana R FletcherEvida Research Consulting, Golden, CO, USA.
Thresia SebastianDepartment of Pediatrics, Denver Health and Hospital Authority, Denver, CO, USA.
Samuel R DominguezDepartment of Pediatric Infectious Diseases, University of Colorado School of Medicine, Aurora, CO, USA.
Melanie KurtzCenter for Health Systems Research, Denver Health and Hospital Authority, Denver, CO, USA.
Sarah K ParkerDepartment of Pediatric Infectious Diseases, University of Colorado School of Medicine, Aurora, CO, USA.
Michael L WilsonDepartment of Pathology and Laboratory Services, Denver Health and Hospital Authority, Denver, CO, USA.ORCID 0000-0002-3857-0100
Timothy C JenkinsDivision of Infectious Diseases, Department of Medicine, Denver Health and Hospital Authority, Denver, CO, USA.
Denver Health Medical Center · USChildren's Hospital Colorado · USAlameda Health System · USNative American Technologies (United States) · US

Funding

Rapid diagnostic tests for adenovirus conjunctivitis in children: An epidemiologic, clinical, and cost-effectiveness evaluationK23HD099925 · NICHD · DENVER HEALTH AND HOSPITAL AUTHORITY · PI FROST, HOLLY · 2019 to 2023
$762k
NICHD NIH HHS K23 HD099925
6 · The paper itself

Abstract

backgroundAcute otitis media (AOM) is the most common reason children are prescribed antibiotics. Bacteria that produce beta-lactamase are an increasingly frequent cause of AOM and may be resistant to amoxicillin, the currently recommended treatment for AOM. We aimed to evaluate the clinical outcomes of children treated with amoxicillin for AOM and assessed whether outcomes vary by infecting pathogen or beta-lactamase production.

methods205 children 6-35 months old diagnosed with AOM and prescribed amoxicillin were included. Bacterial culture and qualitative multiplex real-time polymerase chain reaction were performed on nasopharyngeal swabs collected at enrollment. Parents completed surveys assessing symptoms, antibiotic adherence, and potential adverse events. The primary outcome was treatment failure with amoxicillin. Secondary outcomes included recurrence, symptom improvement, resolution, and adverse drug events (ADE).

results8 children (5.4%) experienced treatment failure and 14 (6.8%) had recurrence. By day 5, 152 (74.1%) children had symptom improvement and 97 (47.3%) had resolution. Parents reported ADE for 56 (27.3%) children. Among 149 children who did not take any amoxicillin before enrollment, 98 (65.8%) had one or more beta-lactamase-producing bacteria. Common bacterial otopathogens were Moraxella catarrhalis (79, 53.0%), Streptococcus pneumoniae (51, 34.2%), Haemophilus influenzae (30, 20.1%), and Staphylococcus aureus (21, 14.1%). Treatment failure did not differ between children that did (5, 5.1%) and did not (3, 5.9%) have beta-lactamase-producing otopathogens (p = .05).

conclusionsAmong children diagnosed with AOM treated with amoxicillin, treatment failure was uncommon and did not differ by pathogen or beta-lactamase production. These data support guidance recommending amoxicillin despite an increasing prevalence of beta-lactamase-producing bacteria.

Indexed as

AmoxicillinOtitis MediaAcute DiseaseAmoxicillin-Potassium Clavulanate CombinationAnti-Bacterial Agentsbeta-LactamasesChildHumansInfantAmoxicillinAmoxicillin-Potassium Clavulanate CombinationAnti-Bacterial Agentsbeta-Lactamasesacute otitis mediaantibiotic stewardshipdiagnosticsPCRpediatricstreatment outcomes

Identifiers

PMID38314853
PMCPMC11494229
OpenAlexW4391540909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.